益诺思 (688710)
Shanghai InnoStar Bio-tech Co., Ltd.
K-Line Chart
No K-line data available
Company NameShanghai InnoStar Bio-Tech Co., Ltd.
Listing Date2024-09-03
Issue Price19.06RMB
Registered Capital14097.961510k RMB
Legal RepresentativeChang Yan
Registered AddressRoom 106, No. 199 Guoshoujing Road, China (Shanghai) Pilot Free Trade Zone
IndustryMedical Services
Main BusinessA comprehensive R&D service (CRO) company primarily providing non-clinical research services for biopharmaceuticals.
Company ProfileShanghai InnoStar Bio-Tech Co., Ltd. is a comprehensive R&D service (CRO) company specializing in providing non-clinical research services for biopharmaceuticals. As one of the earliest enterprises in China to simultaneously hold GLP certification from the NMPA, GLP certification from the OECD, and to have passed the US FDA's GLP inspection, it aligns with international standards and possesses competitive international service capabilities within the industry. The company provides comprehensive new drug research services that comply with domestic and international regulatory submission standards for global pharmaceutical companies and research institutions.
Shanghai InnoStar Bio-Tech Co., Ltd. has undertaken/participated in a total of 24 national, provincial, and regional scientific research projects. It is the sub-project undertaking unit for 2 National Science and Technology Major Projects, the undertaking unit for 1 National Key R&D Program project, and the undertaking unit for 1 Shanghai Municipal Development and Reform Commission Strategic Emerging Industrialization Project. The company has established major innovation platforms such as the "Shanghai New Drug Safety Evaluation Professional Technology Service Platform" and the "Shanghai Biotech Drug PK-PD Engineering Technology Research Center." It has also received the title of "Excellent Project Undertaking Unit in the First Batch of the National Science and Technology Major Project for Significant New Drug Development (Drug Safety Evaluation Demonstration Platform)." The company currently holds 49 patents, including 12 authorized invention patents and 37 utility model patents.
Stock Details
1. Key Indicators
- Total Shares(W): 14097.96
- Circulating A-Shares(W): 9069.40
- Earnings Per Share(RMB): -0.1000
- Net Assets Per Share(RMB): 16.5773
- Operating Revenue(W RMB): 57068.81
- Total Profit(W RMB): 171.13
- **Net Profit Attributable to Parent(W RMB) **: -1478.81
- Net Profit Growth Rate(%): -111.14
- Weighted Return on Equity(%): -0.6200
- Operating Cash Flow Per Share(RMB): 0.1560
- Undistributed Profit Per Share(RMB): 3.3253
- Capital Reserve Per Share(RMB): 12.0125
2. Main Business
The main business covers:
- Professional provision of comprehensive R&D services primarily focused on non-clinical research services for biomedicine (CRO)
3. Company Basic Information
- Company Name: Shanghai Innostar Bio-tech Co., Ltd.
- Listing Date: 2024-09-03
- Industry: Research and Experimental Development
- Address: Room 106, No. 199 Guoshoujing Road, China (Shanghai) Pilot Free Trade Zone
- Website: https://www.innostarbio.com/
- Company Profile: The company was established through the overall transformation of Innostar Co., Ltd. into a joint stock company. On July 31, 2017, the State-owned Assets Supervision and Administration Commission of the State Council issued the "Reply on Issues Concerning the State-owned Equity Management of Shanghai Innostar Bio-tech Co., Ltd." (State-owned Property Rights [2017] No. 730) to China National Pharmaceutical Group, approving the transformation of Innostar Co., Ltd. into a joint stock company. It approved Innostar Co., Ltd. to convert the audited net assets of 56.6342 million yuan as of July 31, 2016 into the share capital of the joint stock company at a ratio of 1:0.882859, resulting in a total share capital of 50 million shares for the joint stock company after conversion. On September 8, 2017, the second interim shareholders' meeting of Innostar Co., Ltd. in 2017 reviewed and approved the transformation of the company from a limited company to a joint stock company. On September 28, 2017, the joint stock company held its founding meeting and first shareholders' meeting, reviewing and approving resolutions including the "Proposal on the Overall Transformation of Shanghai Innostar Bio-tech Co., Ltd. into Shanghai Innostar Bio-tech Co., Ltd." On November 1, 2017, Innostar completed the industrial and commercial change registration procedures for the aforementioned share reform and obtained the "Business License" issued by the Shanghai Administration for Industry and Commerce. Unified Social Credit Code: 91310000555907546T.
4. Top 10 Circulating Shareholders
| Rank | Institution Name | Institution Type | Shares Held (W) | Percentage Held (%) |
|---|---|---|---|---|
| 1 | Shanghai Aopeng Enterprise Management Center (Limited Partnership) | General Legal Person | 1741.24 | 19.20 |
| 2 | Shanghai Zhangjiang Biopharmaceutical Base Development Co., Ltd. | General Legal Person | 1525.01 | 16.81 |
| 3 | Advanced Manufacturing Industry Investment Fund (Limited Partnership) | General Legal Person | 561.40 | 6.19 |
| 4 | Shanghai Biopharmaceutical Public Technology Service Co., Ltd. | General Legal Person | 550.92 | 6.07 |
| 5 | Shanghai Pudong Emerging Industry Investment Co., Ltd. | General Legal Person | 484.05 | 5.34 |
| 6 | Shanghai Technology Venture Capital Co., Ltd. | General Legal Person | 466.75 | 5.15 |
| 7 | Conghua Huazhen Animal Farm (General Partnership) | General Legal Person | 311.17 | 3.43 |
| 8 | China Universal Healthcare Mixed Securities Investment Fund | Fund | 112.15 | 1.24 |
| 9 | ChinaAMC Stable Prosperity Flexible Allocation Mixed Securities Investment Fund | Fund | 93.05 | 1.03 |
| 10 | Caitong Asset Management Innovative Pharmaceuticals Mixed Securities Investment Fund Class A | Fund | 6.54 | 0.07 |
5. Concept Sectors
- Immunotherapy
- CXO Concept
- Innovative Drugs
- Margin Trading & Securities Lending
- High P/E Ratio
- Two-Year New Stock
- Pension Fund
- Planned Reduction
- Small-Cap State-Owned Enterprise
- CSI Central State-Owned Enterprise
- Sci-Tech Innovation State-Owned Enterprise
Remarks
- Data update date: 2025-11-10
- Data source: Public market information